Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

December 4, 2023

AbbVie agrees to acquire ImmunoGen for around $10.1bn

AbbVie has signed a definitive agreement to acquire ImmunoGen, including its flagship cancer therapy ELAHERE (mirvetuximab soravtansine-gynx) in a deal that is expected to speed up the former’s commercial and clinical presence in the solid tumour segment.

AbbVie agrees to acquire ImmunoGen for around $10.1bn